Trial Outcomes & Findings for Molecular and Whole-body MR Imaging in Lymphomas (NCT NCT02389101)

NCT ID: NCT02389101

Last Updated: 2019-08-05

Results Overview

Uptake of 68Ga-DOTANOC in lymphoma expressed as SUVmax

• Recruitment status: COMPLETED
• Study phase: NA
• Target enrollment: 21 participants
• Primary outcome timeframe: Within 30 days prior to start of chemotherapy
• Results posted on: 2019-08-05

Participant Flow

Participant milestones

Measure	Lymphoma 68Ga-DOTANOC PET/CT; Diffusion weighted MRI: PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
Overall Study STARTED	21
Overall Study COMPLETED	21
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Molecular and Whole-body MR Imaging in Lymphomas

Baseline characteristics by cohort

Measure	Study Patients n=21 Participants Patiens with lymphoma
Age, Continuous	66 years n=5 Participants
Sex: Female, Male Female	10 Participants n=5 Participants
Sex: Female, Male Male	11 Participants n=5 Participants

PRIMARY outcome

Timeframe: Within 30 days prior to start of chemotherapy

Population: Lesion with highest radioactivity

Uptake of 68Ga-DOTANOC in lymphoma expressed as SUVmax

Outcome measures

Measure	Lymphoma n=21 Lymphomatous lesion Uptake of 68Ga-DOTANOC
68Ga-DOTANOC Uptake in Lymphomas With PET/CT	3.1 Standardized Uptake Value Interval 1.9 to 9.8

Adverse Events

Lymphoma

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Heikki Minn, MD

Turku Univesrity Hospital, Turku, Finland

Phone: +35823130000

Email: heikki.minn@utu.fi

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place